Efficacy of PD-1/PD-L1 inhibitors for recurrent or metastatic cervical cancer and its effect on serum levels of SCC-Ag,CEA,and CA125
Objective To investigate the efficacy of programmed death receptor-1(PD-1)/programmed death-ligand 1(PD-L1)inhibitors in the treatment of recurrent or metastatic cervical cancer and its effect on serum levels of squamous cell carcinoma antigen(SCC-Ag),carcinoembryonic antigen(CEA),and carbohydrate antigen 125(CA125)in patients.Methods This study was a retrospective study.Ninety patients with cervical cancer treated at Lishui Municipal Central Hospital between January 2019 and December 2022 were randomly divided into two groups.Forty-five patients in the control group received routine radiotherapy and chemotherapy,while forty-five patients in the observation group received PD-1/PD-L1 inhibitors in addition to the treatment provided to the control group.The effectiveness and safety were compared between the two groups.Results The effectiveness in the observation group was superior to that in the control group(P＜0.05).After treatment,the levels of serum tumor markers,including SCC-Ag,CA125,CEA,and human epididymal protein 4,were significantly lower in the observation group compared with the control group(t=5.44,6.20,14.74,4.06,all P＜0.001).After treatment,the levels of interferon-y,interleukin-2,and interleukin-6 in the observation group were significantly lower compared with the control group(t=6.24,8.95,8.38,all P＜0.001).After treatment,the levels of CD3+,CD4+,and CD4+/CD8+in the observation group were significantly higher compared with those in the control group(t=8.82,6.53,5.27,all P＜0.001).After treatment,the Functional Assessment of Cancer Therapy-Cervix score in the observation group was significantly higher than that in the control group(t=4.35,4.35,5.17,5.24,all P＜0.001).The incidence of various adverse reactions in the observation group was significantly lower than that in the control group(x2=3.85,3.87,5.08,4.44,all P＜0.05).The cumulative survival rate in the observation group was significantly higher than that in the control group[60.00％(27/45)vs.40.00％(18/45),P＜0.05].The median survival time in the observation group was significantly longer than that in the control group(365 days vs.222 days,P＜0.05).Conclusion PD-1/PD-L1 inhibitors are effective in the treatment of recurrent or metastatic cervical cancer.They can reduce the serum levels of SCC-Ag,CEA,and CA125,prolong the survival time of patients,and improve their quality of life.
Uterine cervical neoplasmsBiomarkers,tumorImmunityQuality of lifeDrug-related side effects and adverse reactions
NETL
NSTL
万方数据
